Unicycive Therapeutics, Inc.

NasdaqCM:UNCY Stock Report

Market Cap: US$69.6m

Unicycive Therapeutics Past Earnings Performance

Past criteria checks 0/6

Unicycive Therapeutics's earnings have been declining at an average annual rate of -48.9%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 46.1% per year.

Key information

-48.9%

Earnings growth rate

-28.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate46.1%
Return on equity-82.6%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely

Dec 11
We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely

We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 21
We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

Feb 16
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?

We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Aug 18
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate

Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Mar 08
Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely

Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

Sep 07

Unicycive Therapeutics GAAP EPS of -$0.24

Aug 16

Unicycive inks licensing deal for kidney disease drug Renazorb in Asia

Jul 18

Revenue & Expenses Breakdown

How Unicycive Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:UNCY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-241019
30 Jun 240-241019
31 Mar 240-32917
31 Dec 231-31913
30 Sep 231-29813
30 Jun 232-30714
31 Mar 232-29714
31 Dec 221-18712
30 Sep 221-15610
30 Jun 220-1569
31 Mar 220-1348
31 Dec 210-1036
30 Sep 210-825
30 Jun 210-412
31 Mar 210-311
31 Dec 200-211
30 Sep 200-211
30 Jun 200-211
31 Mar 200-211
31 Dec 190-211

Quality Earnings: UNCY is currently unprofitable.

Growing Profit Margin: UNCY is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: UNCY is unprofitable, and losses have increased over the past 5 years at a rate of 48.9% per year.

Accelerating Growth: Unable to compare UNCY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UNCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: UNCY has a negative Return on Equity (-82.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:00
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Unicycive Therapeutics, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Kumaraguru RajaBrookline Capital Markets
Antonio ArceH.C. Wainwright & Co.